USA News Group News Commentary
Issued on behalf of Avant Technologies Inc.
VANCOUVER, BC, Sept. 25, 2025 /PRNewswire/ -- America's aging demographics are creating unprecedented demand for precision healthcare solutions, with population projections showing nearly one in four Americans will be over 65 by 2060[1]. Gene therapy approvals continue accelerating as the FDA recently approved breakthrough treatments targeting rare diseases[2], while AI-powered diagnostic platforms are transforming how clinicians detect conditions before symptoms appear[3]. These market-wide trends are positioning early-stage companies across diagnostics, gene therapy, and personalized medicine for significant growth opportunities through Avant Technologies, Inc. (OTCQB: AVAI), uniQure N.V. (NASDAQ: QURE), Veracyte, Inc. (NASDAQ: VCYT), Humana Inc. (NYSE: HUM), and Editas Medicine, Inc. (NASDAQ: EDIT).
Alternative payment models in Medicare are expanding to reward quality outcomes over volume, creating reimbursement tailwinds for innovative therapies that demonstrate clear patient benefit[4]. Meanwhile, healthcare joint ventures are surging as systems seek partners with specialized expertise to accelerate market entry and operational efficiency, providing crucial capital pathways for companies developing next-generation treatments[5].
Avant Technologies, Inc. (OTCQB: AVAI) has executed a strategic pivot into the high-growth longevity biotechnology sector through a transformative joint venture with Singapore-based Austrianova (SGAustria Pte. Ltd.), establishing Klothonova, Inc. as a 50/50 partnership focused on pioneering cell-based therapies utilizing encapsulated Klotho-producing cells. This agreement positions Avant at the forefront of anti-aging therapeutics by leveraging Austrianova's proprietary cell-encapsulation technology and decades of expertise in cell biology and GMP-grade manufacturing.
The joint venture targets multiple lucrative therapeutic areas including Alzheimer's disease, heart disease, cancer, kidney disease, and other age-related conditions through innovative treatments based on Klotho protein overexpression. Austrianova brings substantial intellectual property backed by over 50 peer-reviewed publications and established partnerships with global pharmaceutical companies, while Avant provides capital and operational resources to accelerate Klothonova's development pipeline.
"We are thrilled to partner with Austrianova, whose world-class expertise in cell encapsulation and GMP manufacturing complements our vision for advancing transformative healthcare solutions," said Chris Winter, CEO at Avant Technologies. "Klothonova represents a significant step toward addressing some of the most pressing medical challenges of our time."
The scientific foundation appears compelling based on extensive research demonstrating Klotho's therapeutic potential. Studies show that higher Klotho levels correlate with up to 30% increased lifespan, while individuals with lowest Klotho levels had 31% higher mortality rates than those with higher levels. Critically, natural Klotho levels drop by 50% after age 40, creating substantial therapeutic opportunities for intervention.
Klotho, discovered in 1997 and primarily produced in kidneys and brain tissue, functions as a crucial "longevity protein" that modulates aging processes while affecting brain, heart, kidneys, and immune function simultaneously. Research has linked Klotho to improved cognitive function, cardiovascular health, and kidney function, with demonstrated potential in combating age-related diseases.
"This joint venture with Avant Technologies allows us to combine our proprietary technologies with Avant's resources to accelerate the development of Klotho-based therapies," added Brian Salmons, CEO at Austrianova. "We are excited about the potential to improve patient outcomes and promote healthier, longer lives."
The market opportunity appears substantial across multiple therapeutic areas. The global Alzheimer's disease market is projected to reach $32.8 billion by 2033, while cardiovascular disease remains the world's leading cause of death, and kidney disease affects 850 million people worldwide. Austrianova's proven Cell-in-a-Box® technology with 30+ years of development enables sustained, controlled delivery of Klotho-producing cells through established GMP manufacturing capabilities.
This strategic transformation positions Avant within the rapidly expanding longevity biotechnology sector, with Klothonova's exclusive licensing arrangements and equal ownership structure creating multiple potential value creation pathways as Klotho-based treatments advance toward clinical validation and commercialization across global markets.
CONTINUED… Read this and more news for Avant Technologies Inc. at https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ and https://usanewsgroup.com/avai-profile/
uniQure N.V. (NASDAQ: QURE) achieved a significant milestone in neurodegeneration treatment as its pivotal Phase I/II study of AMT-130 for Huntington's disease met the primary endpoint with high-dose treatment demonstrating statistically significant 75% disease slowing at 36 months. The gene therapy candidate also showed a 60% slowing of disease progression as measured by Total Functional Capacity, a key secondary endpoint, while mean cerebrospinal fluid NfL levels remained below baseline. uniQure plans to submit a Biologics License Application to the FDA in the first quarter of 2026, with anticipated U.S. launch later that year pending approval.
"We are incredibly excited about these topline results and what they may represent for individuals and families affected by Huntington's disease," said Walid Abi-Saab, M.D., chief medical officer of uniQure. "These findings reinforce our conviction that AMT-130 has the potential to fundamentally transform the treatment landscape for Huntington's disease, while also providing important evidence supporting one-time, precision-delivered gene therapies for the treatment of neurological disorders. We are eager to discuss the data with the FDA at our pre-BLA meeting expected later this year, with the goal of submitting a BLA in the first quarter of 2026."
AMT-130 has received Breakthrough Therapy designation and Regenerative Medicine Advanced Therapy designation from the FDA, positioning uniQure to potentially deliver the first approved therapy for this devastating inherited neurodegenerative disorder. The company continues enrolling patients in additional cohorts while advancing its pipeline of proprietary gene therapies for severe diseases including refractory temporal lobe epilepsy, ALS, and Fabry disease.
Veracyte, Inc. (NASDAQ: VCYT) will present groundbreaking validation data for a molecular signature predicting hormone therapy benefit in men with recurrent prostate cancer at ASTRO 2025, marking the first prospective validation of such a biomarker in this patient population. The genomic diagnostics company's research, derived using its Decipher GRID platform, represents one of nine Decipher-focused abstracts being presented at the conference, with six selected for podium presentations. Veracyte's Decipher GRID database includes more than 200,000 whole-transcriptome profiles from patients with urologic cancers, representing the largest repository of its kind in prostate cancer research.
"We look forward to the presentation of important new data examining the role of adverse molecular features in predicting disease progression and treatment response for patients with prostate cancer," said Elai Davicioni, Ph.D., medical director for Urology at Veracyte. "Such insights will ultimately make prostate cancer care more precise, giving greater molecular dimension to the classification and treatment of the disease. We believe that our Decipher GRID research tool, combined with our extensive database of prostate tumor whole-transcriptome-derived genomic profiles-the largest of its kind in prostate cancer research-uniquely positions Veracyte to usher in the next generation of cancer diagnostics."
The company's Decipher Prostate test has achieved "Level I" evidence status and inclusion in the NCCN Guidelines risk-stratification table, with clinical utility demonstrated across more than 90 studies involving over 200,000 patients. Veracyte's expanding research collaborations and comprehensive genomic database continue to drive innovation in precision oncology diagnostics across multiple cancer types.
Humana Inc. (NYSE: HUM) is expanding its value-based partnership with TailorCare to deliver specialized musculoskeletal care to Medicare Advantage members in Dallas and Denver, building on the success of existing programs in Atlanta that optimize health outcomes for patients with joint, back, and muscle pain. The expansion will provide comprehensive care coordination and evidence-based MSK navigation support to qualifying Humana members beginning in November 2025 and January 2026, respectively. This strategic partnership addresses the significant healthcare burden of musculoskeletal conditions, which affect nearly 1 in 2 Americans and cost the U.S. more than $400 billion annually.
"Humana members can expect to be connected to musculoskeletal care that is deeply personalized, proactive, and built around their individual needs," said Rachel Winokur, founder and CEO of TailorCare. "We're proud to expand our partnership and ensure more Humana members have the trusted support they deserve at every step of their care journey."
The partnership leverages TailorCare's advanced home-based exercise programs featuring 225+ evidence-based clinical pathways, certified health coaching, and sensorless motion tracking technology for dynamic progress monitoring. Humana's commitment to value-based care models continues to drive improved patient outcomes while managing healthcare costs across its Medicare Advantage network serving millions of members nationwide.
Editas Medicine, Inc. (NASDAQ: EDIT) nominated EDIT-401 as its lead in vivo development candidate, an experimental gene editing medicine targeting hyperlipidemia that achieved approximately 90% mean LDL cholesterol reduction with a single dose in non-human primate studies. The LDLR-targeted therapy represents a potentially transformative one-time treatment designed for lifelong benefit, significantly outperforming standard-of-care therapies that demonstrate 40-60% mean LDL-C reduction. Editas Medicine expects to achieve human proof-of-concept data by the end of 2026, with plans to submit an investigational new drug application by mid-2026.
"Today's nomination of EDIT-401 as our lead in vivo development candidate is a significant milestone in our long-term vision to lead the field of in vivo programmable gene editing," said Gilmore O'Neill, M.B., M.M.Sc., President and CEO of Editas Medicine. "At Editas Medicine, we believe in vivo is the future of medicine. With EDIT-401, we're advancing our differentiated upregulation strategy to develop a next-generation medicine that can deliver lasting impact for patients."
The company maintains a strong financial position with $178.5 million in cash, cash equivalents, and marketable securities as of June 30, 2025, providing operational runway into the second quarter of 2027. Editas Medicine continues advancing its pipeline of in vivo gene editing candidates while planning to identify and disclose an additional target cell type or tissue by the end of 2025.
Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/
CONTACT:
USA NEWS GROUP
info@usanewsgroup.com
(604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
SOURCES CITED:
- https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1660889/full
- https://www.cgtlive.com/view/fda-activity-recap-august-papillomatosis-gene-therapy-approval-eli-cel-labelling-update
- https://blog.lifesciencenation.com/2025/08/12/investing-in-early-stage-diagnostics-innovation/
- https://www.ama-assn.org/practice-management/medicare-medicaid/medicare-basics-series-advancing-value-based-care-alternative
- https://www.advisory.com/daily-briefing/2025/08/25/urgent-care-ec
Logo: https://mma.prnewswire.com/media/2603685/5530327/USA_News_Group_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/healthcare-innovation-accelerates-as-four-converging-forces-drive-early-intervention-focus-302566992.html
